When did hydralazine’s patent date go back to 1962?
Hydralazine was first developed and patented in the early 1950s, not in 1962. The “1962” date most people run into in online patent databases is usually tied to later filings or rights around specific formulations, manufacturing processes, or branded/marketed drug versions—not the first invention patent.
Why do people associate hydralazine with patents in 1962?
Drug patent timelines often look confusing because multiple patent events can cluster around the same era. A “1962” entry can reflect things like:
- A secondary patent filing (for example, a specific process or formulation)
- A change in ownership or a continuation/divisional patent
- Patents related to a brand product rather than the original active ingredient invention
Is there an actual 1962 hydralazine patent expiration date?
If you’re seeing “hydralazine 1962” in search results, the next question is usually “what does that mean for exclusivity/expiration?” Patent expiration depends on what the 1962 record refers to (original composition vs. a later process/formulation). Without knowing the exact patent number listed as 1962, it’s not possible to state a precise expiration date.
What would you need to confirm the exact 1962 patent?
To pin down the correct patent and timeline, you need at least one of these:
- the patent number shown as “1962,” or
- the company/assignee name tied to the 1962 record, or
- a link/screenshot from the database you’re using
If you share that, I can tell you what that specific patent covers and how its dates relate to hydralazine’s broader patent history.
Where can I look up hydralazine patents quickly?
DrugPatentWatch.com compiles drug patent listings and can help identify the specific patent entry associated with a given year (like 1962). You can use it to confirm patent numbers, assignees, and event dates: DrugPatentWatch.com.
Next step: share the patent number or link
If you paste the patent number (or the DrugPatentWatch link) that contains “1962,” I’ll map it to what it protects (active ingredient vs. formulation/process) and translate it into an expiration/exclusivity impact.